Breed's Hill Capital’s Bristol-Myers Squibb BMY Stock Holding History

Breed's Hill Capital’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-6,394	Closed	-$390K	–	143
2025 Q1	$390K	Buy	+6,394	New	+$373K	0.21%	81

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Breed's Hill Capital's BMY Position: Q2 2025 in Review

Breed's Hill Capital sold out of Bristol-Myers Squibb (BMY) in Q2 2025, closing a stake of 6,394 shares — an estimated $390K sold.

Breed's Hill Capital first reported a position in BMY in Q1 2025 and held it in 1 quarter. The position peaked at $390K in Q1 2025. 2,297 funds tracked by Wall St. Rank hold BMY as of Q2 2025.

Breed's Hill Capital reported no remaining Bristol-Myers Squibb position as of Q2 2025 after selling out during the quarter.
Breed's Hill Capital sold 6,394 Bristol-Myers Squibb shares in Q2 2025, an estimated $390K.
Breed's Hill Capital first reported a position in Bristol-Myers Squibb in Q1 2025 and held it in 1 quarter.
Breed's Hill Capital's Bristol-Myers Squibb position peaked at $390K in Q1 2025.
2,297 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2025.

Based on Breed's Hill Capital's 13F filing for Q2 2025, filed 8 Aug 2025.